關於癌症疫苗臨床前研究的業務進展更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 整體而言，所發表之研究均呈現一致主題：通過理性設計的癌症疫苗，於多個腫瘤靶點及疫苗構建 體之臨床前模型中，均展現強勁免疫原性及顯著的抗腫瘤活性。在發表中展示之該等數據充分印證 順譜醫藥科技從抗原篩選轉化至功能性免疫反應及腫瘤控制上之優勢。在此基礎上，順譜醫藥科技 正加快推進最具潛力之研發項目的新藥臨床試驗申請（IND）支持性研究，並期望透過策略性合作與 全球協作，加快將選定候選疫苗推進至早期臨床開發階段。 務請注意，該研究目前僅處於臨床前階段，本公司尚未開始就該等疫苗進行臨床試驗，故目前概不能 保證相關成果。因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 香港，二零二六年三月三十一日 於本公告日期，本公司執行董事為李澤鉅先生（主席）、甘慶林 ...

Performance Summary - Fuyao Glass (03606.HK) reported a revenue of approximately 45.787 billion yuan for 2025, representing a year-on-year increase of 16.65%, with a net profit of about 9.312 billion yuan, up 24.2% [1] - Hengan International (01044.HK) achieved a revenue of 23.069 billion yuan in 2025, a 1.8% increase year-on-year, and a net profit of 2.535 billion yuan, up 10.3%. E-commerce and new retail sales revenue grew by 10.1%, with an annual gross margin improvement to approximately 33.8% [1] - Sunac China (01918.HK) expects a loss between 12 billion to 13 billion yuan for 2025, a reduction compared to the previous year, primarily due to gains from overseas debt restructuring [1] - Tencent Music (01698.HK) reported total revenue of 32.9 billion yuan for 2025, a 15.8% year-on-year increase, with a net profit of 11.06 billion yuan, up 66.4% [2] - China Eastern Education (00667.HK) achieved a revenue of 4.616 billion yuan in 2025, a 12.1% increase, with adjusted net profit of 792 million yuan, up 50.9% [4] - Hong Kong Electric (02638.HK) reported a revenue of 12.125 billion yuan for 2025, a 0.6% increase, and a net profit of 3.149 billion yuan, up 1.2% [5] - Longjiang Life Science (00775.HK) reported a revenue of 5.41 billion HKD, a 2% decrease, with a net loss of 187 million HKD, an increase of 47.61% year-on-year [3] Company News - Weisheng Holdings (03393.HK) won a supply contract for reclosers from CEMIG, Brazil's largest power company, valued at 138 million Brazilian Reais (approximately 182 million yuan or 206 million HKD), to be delivered in batches over the next two years [9] - Hong Kong International Holdings (00480.HK) partnered with Jiaxing Xiutuo Construction Investment Group to acquire a commercial land plot in Jiaxing for approximately 216.4 million yuan, planning to develop a shopping center [9] Financing and Buyback Activities - Xindong Company (02400.HK) repurchased 108,000 shares at a cost of approximately 7.911 million HKD, with prices ranging from 72.00 to 75.05 HKD [16] - Yum China (09987.HK) repurchased 18,500 shares for about 7.714 million HKD, with prices between 414.8 and 420.6 HKD [16] - CNOOC Oilfield Services (02883.HK) completed the issuance of 5 billion yuan in bonds through its wholly-owned overseas subsidiary [17]

Financial Performance - For the fiscal year ending December 31, 2025, the company reported a loss attributable to shareholders of HKD 186.8 million, an increase of HKD 60.2 million compared to the previous year, primarily due to increased R&D expenses of HKD 66.5 million[3]. - After excluding one-time gains from the sale of vineyards in 2024 and special items in 2025, the company's after-tax net profit from its core business was HKD 130.8 million, an increase of HKD 42.6 million from 2024[3]. - Total revenue for the year ended December 31, 2025, was HKD 5,410,228,000, a decrease of 2.02% from HKD 5,522,674,000 in 2024[30]. - The annual loss for 2025 was HKD 188,447,000, compared to a loss of HKD 126,554,000 in 2024, with basic loss per share increasing to HKD 1.94 from HKD 1.32[30]. - The company reported a comprehensive income of HKD 122,703,000 for 2025, a recovery from a comprehensive loss of HKD 677,705,000 in 2024[31]. - The company reported a net loss of HKD 188,447 thousand for the year ending December 31, 2025, compared to a net loss of HKD 126,554 thousand in 2024[50]. Revenue Breakdown - Revenue from the healthcare products business was HKD 3.37 billion, a decrease of 2% compared to HKD 3.45 billion in 2024[15]. - Agricultural-related business recorded revenue of HKD 2.037 billion, down 2% from HKD 2.07 billion in 2024[17]. - Revenue from agricultural-related business was HKD 1,886,708,000, down from HKD 1,906,977,000 in 2024, representing a decline of 1.93%[40]. - Revenue from healthcare products decreased to HKD 3,371,935,000 from HKD 3,451,588,000, a drop of 2.31%[40]. - Revenue from the Asia-Pacific region was HKD 2,789,263 thousand in 2025, slightly down from HKD 2,813,144 thousand in 2024, a decrease of about 0.8%[52]. - Revenue from North America decreased to HKD 2,619,555 thousand in 2025 from HKD 2,708,189 thousand in 2024, a decline of approximately 3.3%[52]. Corporate Developments - The company underwent a significant corporate restructuring aimed at enhancing its pharmaceutical and diagnostic research capabilities and attracting more professional talent[4]. - In October 2025, RNAZ completed the acquisition of the melanoma cancer vaccine seviprotimut-L from the company, focusing on innovative immuno-oncology and RNA therapies for high-risk and late-stage cancers[4]. - The company established a wholly-owned subsidiary, Sequencio Therapeutics, to integrate all cancer vaccine R&D projects and focus on developing therapeutic cancer vaccines[6]. - The company strategically invested in Pharus Inc. to enhance early lung cancer detection accuracy using OncoSweep™ technology[13]. Research and Development - The group invested approximately HKD 320.6 million in research and development activities in 2025[26]. - DWTX announced positive interim results from a Phase 2b clinical trial of Halneuron®, showing a higher pain relief rate compared to the placebo group[8]. - RNAZ's main therapeutic candidate, TTX-MC138, completed Phase 1 clinical trials, achieving primary safety endpoints and preparing for Phase 2a trials in colorectal cancer patients[10]. - Sequencio is actively advancing multiple promising candidates into clinical trials, aiming to provide substantial clinical benefits to patients[12]. - The company is developing an AI-driven platform to optimize immunogenicity predictions, enhancing the design of cancer vaccines and improving clinical efficacy potential[12]. Financial Position - The group’s total assets as of December 31, 2025, were approximately HKD 11.84 billion, with net assets amounting to HKD 3.85 billion, equivalent to HKD 0.40 per share[22]. - The total bank borrowings amounted to HKD 6.0281 billion, with interest expenses totaling HKD 239.1 million for the year[22]. - The group’s net debt to total equity ratio was approximately 58.52% as of December 31, 2025[22]. - The company’s total equity increased to HKD 3,846,084,000 in 2025 from HKD 3,511,548,000 in 2024[33]. - The group reported a current liability exceeding current assets by HKD 461,180,000 as of December 31, 2025[36]. Employee and Operational Costs - Employee costs for the year were approximately HKD 1,238.4 million, a slight increase of 0.1% compared to the previous year[28]. - Financial expenses decreased to HKD 266,894,000 from HKD 337,184,000, a reduction of 20.7%[44]. - Tax expenses for 2025 amounted to HKD 170,436,000, significantly higher than HKD 35,072,000 in 2024[45]. Shareholder Information - The company did not recommend a final dividend for the year ending December 31, 2025 (2024: none)[47]. - The 2026 Annual General Meeting is scheduled for May 21, 2026[60]. - The record date for shareholders eligible to attend and vote at the 2026 Annual General Meeting is May 21, 2026[61]. - The company will suspend share transfer registration from May 18, 2026, to May 21, 2026, inclusive[61].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 誠如先前公告所述，於二零二四年，本公司與一家專注研發舒緩痛楚及神經痛症藥物之納 斯達克上市公司 Dogwood Therapeutics, Inc.（「Dogwood」）完成交易。本公司現時持有 Dogwood 之多數股權。於二零二五年，本公司將處於後期研發階段之黑色素瘤疫苗 seviprotimut-L出售予另一家納斯達克上市公司 TransCode Therapeutics, Inc.（「TransCode」） 以獲取其股權。 隨 著 本公司持有 Sequencio 、 TransCode 及 Dogwood ， 本公司 已建立 研發平台， 其多元化研發組合涵蓋早期及後期項目，聚焦於當前醫療需求尚未得到充分滿足之領域。 承董事會命 長江生命科技集團有限公司 公司秘書 （於開曼群島註冊成立之有限公司） （股份代號：0775） 就成立順譜醫藥科技有限公司 以全力推進治療性癌症疫苗研發之 自願性公告 長江 ...

長江生命科技集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司將於 二零二六年三月十七日（星期二）於香港舉行董事會會議，以（其中包括）批准刊發本公司 及其附屬公司截至二零二五年十二月三十一日止財政年度之業績，以及考慮派發末期股息。 承董事會命 長江生命科技集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) （股份代號：0775） 董事會召開日期 公司秘書 楊逸芝 於本文件日期，本公司執行董事為李澤鉅先生（主席）、甘慶林先生、葉德銓先生、 余英才先生、Lance Richard Lee Yuen 先生及杜健明醫生；非執行董事為 Peter Peace Tulloch 先生、郭李綺華女士（獨立非執行董事）、關啟昌先生（獨立非執行董事）、Paul Joseph Tighe 先生（獨立非執行董事）及羅弼士先生（獨立非執行董事）。 香港，二零二六年三月五日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本總額 ...

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to support its research projects, particularly in therapeutic cancer vaccines, amidst a complex global drug development environment [1][5]. Group 1: Company Developments - Changjiang Life Sciences Technology's stock price increased by 3.57% to HKD 0.87, with a trading volume of HKD 35.51 million [1][5]. - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1][5]. Group 2: Strategic Initiatives - The committee is a strategic organization that will provide scientific, clinical, and regulatory guidance to accelerate the company's research projects, including several therapeutic cancer vaccines that are preparing for clinical trials [1][5]. - The Scientific Advisory Committee will also offer professional resources to help the company navigate the increasingly complex global drug development landscape, mitigate risks, and expedite regulatory approvals and patient access [1][5].

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to enhance its research capabilities and navigate the complexities of global drug development [1] Group 1: Company Developments - The stock of Changjiang Life Sciences Technology has seen an increase of over 4%, currently trading at 0.87 HKD with a transaction volume of 31.7098 million HKD [1] - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and the industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1] Group 2: Strategic Initiatives - The committee is a strategic organization aimed at providing scientific, clinical, and regulatory guidance to support the company's research projects, particularly in the development of therapeutic cancer vaccines [1] - The Scientific Advisory Committee will offer professional resources to help the company address the increasingly complex global drug development environment, mitigate risks, and expedite regulatory approvals and patient access [1]

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to enhance its research capabilities and navigate the complexities of global drug development [1] Group 1: Company Developments - Changjiang Life Sciences Technology's stock rose over 4%, currently trading at 0.87 HKD with a transaction volume of 31.7098 million HKD [1] - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and the industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1] - The committee will provide strategic guidance on scientific, clinical, and regulatory matters to support the company's research projects, particularly in the development of therapeutic cancer vaccines [1] Group 2: Strategic Implications - The establishment of the committee aims to mitigate risks and accelerate the process of obtaining regulatory approvals and patient access in an increasingly complex global drug development environment [1] - The committee will also offer professional resources to assist the company in advancing its research initiatives [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本總額： HKD 1,500,000,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年1月31日 狀 ...